_	_		_		
TA.	FISH	8z.	RICHA	RDSON	P.C.

Approved for use through xx/xx/xxxx. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**REQUEST FOR** NUED EXAMINATION (RCE)

Subsection (b) of 35 U.S.C. §132, effective on May 29, 2000, provides for continued examination of a utility or plant application filed on or after June 8, 1995. See The American Inventors Protection Act of 1999 (AIPA).

•		
Application Number	09/449,435	_,
Filing Date	November 24, 1999	
First Named Inventor	Paul Frederick Koeppe et al.	2./
Group Art Unit	2836	, .
Examiner Name	R. Rios Cuevas	
Attorney Docket Number	05770-092001	

	on (RCE) under 37 C.F.R. §1.114 of the above-identified application.
This is a Request for Continued Examination	on (RCE) under 37 C.F.R. §1.114 of the above scale and applicant may wish to
Tills is a recognition of the affective on May 20, 20	000. If the above-identified application was filed prior to May 29, 2000, applicant may wish to
NOTE: 37 C.F.R. §1.114 is effective oil way 23, 20	100. If the above-identified application was first place in the patient term (PPA) under 37 C.F.R. §1.53(d) (PTO/SB/29) instead of a RCE to be eligible for the patient term (PPA) under 37 C.F.R. §1.53(d) (PTO/SB/29) instead of a RCE to be eligible for the patient term (PPA) under 37 C.F.R. §1.53(d) (PTO/SB/29) instead of a RCE to be eligible for the patient term (PPA) under 37 C.F.R. §1.53(d) (PTO/SB/29) instead of a RCE to be eligible for the patient term (PPA) under 37 C.F.R. §1.53(d) (PTO/SB/29) instead of a RCE to be eligible for the patient term (PPA) under 37 C.F.R. §1.53(d) (PTO/SB/29) instead of a RCE to be eligible for the patient term (PPA) under 37 C.F.R. §1.53(d) (PTO/SB/29) instead of a RCE to be eligible for the patient term (PPA) under 37 C.F.R. §1.53(d) (PTO/SB/29) instead of a RCE to be eligible for the patient term (PPA) under 37 C.F.R. §1.53(d) (PTO/SB/29) instead of a RCE to be eligible for the patient term (PPA) under 37 C.F.R. §1.53(d) (PTO/SB/29) instead of a RCE to be eligible for the patient term (PPA) under 37 C.F.R. §1.53(d) (PTO/SB/29) instead of a RCE to be eligible for the patient term (PPA) under 37 C.F.R. §1.53(d) (PTO/SB/29) instead of a RCE to be eligible for the patient term (PPA) under 37 C.F.R. §1.53(d) (PTO/SB/29) instead of a RCE to be eligible for the patient term (PPA) under 37 C.F.R. §1.53(d) (PTO/SB/29) instead of a RCE to be eligible for the patient term (PPA) under 37 C.F.R. §1.53(d) (PTO/SB/29) instead of a RCE to be eligible for the patient term (PTO/SB/29) instead of a RCE to be eligible for the patient term (PTO/SB/29) instead of a RCE to be eligible for the patient term (PTO/SB/29) instead of a RCE to be eligible for the patient term (PTO/SB/29) instead of a RCE to be eligible for the patient term (PTO/SB/29) instead of a RCE to be eligible for the patient term (PTO/SB/29) instead of a RCE to be eligible for the patient term (PTO/SB/29) instead of a RCE to be eligible for the patient term (PTO/SB/29) instead of a RCE to be eligible for the patient term (PTO/SB/2
consider filing a continued prosecution application (C	to Application Examination and Provisional Application Practice, Interim Rule, 65 Fed. Reg. 14, 2000), which established RCF practice.
" to an delana of the AIDA See Changes	to Application Examination and Froviolence, Application
adjustment provisions of the AIFA. Gee Changes	(Apr. 11, 2000), which established RCF practice.
14865 (Mar. 20. 2000), 1233 Off, Gaz. Pat. Office 47	(Apr. 11, 2000), Which combined that product

14003 (Mar. 20, 20							
a. Previous i. Co (An ii. Co iii. Otl b. Enclosed ii. Aff iii. Inf iv. Ot	nsider the amendment(s)/reply under 3 y unentered amendment(s) referred to above will nsider the arguments in the Appeal Bridger    nendment/Reply   idavit(s)/Declaration(s)   ormation Disclosure Statement (IDS)   her Petition for Three Month Extension   s   iion of action on the above-identified apmonths. (Period of suspension shall not excee	er or Reply Brief previously filed on					
b. Other  3. Fee The RCE fee under 37 C.F.R. §1.17(e) is required by 37 C.F.R. §1.114 when the RCE is filed.  a. The Director is hereby authorized to charge the following fees, or credit any overpayments, to Deposit Account No. 06-1050 i. RCE fee required under 37 C.F.R. §1.17(e) ii. Extension of time fee (37 C.F.R. §1.136 and 1.17) iii. Other Any deficiencies b. Check in the amount of \$750 enclosed c. Payment by credit card (Form PTO-2038 enclosed)							
	SIGNATURE OF APPLICANT	ATTORNEY OR AGENT REQUIRED					
Name (Print/Type)	Frank R. Occhiuti F. A. LICHAU	Registration No. (Attorney/Agent) 35,306— 9/9 42					
Signature	Whave	Date April 8, 2003					
	OFDIEIOATE OF M	AILING OR TRANSMISSION					
	CERTIFICATE OF M.	ALLING OK TRANSMISSION					
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Commissioner for Patents, Box RCE, Washington, DC 20231 or facsimile transmitted to the U.S. Patent and Trademark Office on: April 8, 2008  Name (Print/Type) Matthew G/Dob/erty							
Name (Print/Type) Signature	Man Wohl	Date April 8, 2003					
Signature							

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send fees and completed forms to the following address: Commissioner for Patents, Box RCE, Washington, DC 20231.